Colchicine in behçet syndrome: A longterm survey of patients in a controlled trial

Journal of Rheumatology

Volumn 41, Issue 4, 2014, Pages 735-738

  Hamuryudan, Vedat ^a   Hatemi, Gulen ^a   Tascilar, Koray ^a   Yurdakul, Sebahattin ^a   Mat, Cem ^a   Ozyazgan, Yilmaz ^a   Seyahi, Emire ^a   Ugurlu, Serdal ^a   Yazici, Hasan ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Beh et syndrome; Colchicine; Prognosis

Indexed keywords

COLCHICINE; IMMUNOSUPPRESSIVE AGENT; PLACEBO; CORTICOSTEROID;

ADULT; ARTICLE; BEHCET DISEASE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; ADOLESCENT; AGE; BEHCET SYNDROME; COMPARATIVE STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; EARLY DIAGNOSIS; FOLLOW UP; INFORMATION PROCESSING; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; RETREATMENT; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DIFFERENCE; TIME; YOUNG ADULT;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGE FACTORS; BEHCET SYNDROME; COLCHICINE; DATA COLLECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EARLY DIAGNOSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; REFERENCE VALUES; RETREATMENT; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 84897435833     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.130847     Document Type: Article

References (14)

1. Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V, et al. The long-term mortality and morbidity of Behçet syndrome. A 2-decade outcome survey of 387 patients followed in a dedicated center. Medicine 2003;82:60-76.
2. Seyahi E, Yazici H. Prognosis in Behçet's syndrome. In: Yazici Y, Yazici H. Behçet's syndrome. New York: Springer; 2010:285-98.
3. Yazici H, Tuzun Y, Pazarli H, Yurdakul S, Ozyazgan Y, Ozdoǧan H, et al. Influence of age at onset and patient's sex on the prevalence and severity of Behçet's syndrome. Ann Rheum Dis 1984;43:783-9.
4. Hamuryudan V, Koetter I. Medical management of Behçet's syndrome. In: Yazici Y, Yazici H. Behçet's syndrome. New York: Springer; 2010:317-38.
5. Ben-Chetrit E, Levy M. Colchicine: 1998 update. Semin Arthritis Rheum 1998;28:48-59.
6. Turkstra F, van Vugt RM, Dijkmans BA, Yazici Y, Yazici H. Results of a questionnaire on the treatment of patients with Behçet's syndrome: a trend for more intensive treatment. Clin Exp Rheumatol 2012;3 Suppl 72:S10-136.
7. Aktulga E, Altac M, Muftuoglu A, Ozyazgan Y, Pazarli H, Tuzun H, et al. A double blind study of colchicine in Behçet's disease. Haematologica 1980;65:399-402.
8. Yurdakul S, Mat C, Tuzun Y, Ozyazgan Y, Hamuryudan V, Uysal O, et al. A double blind study of colchicine in Behçet's syndrome. Arthritis Rheum 2001;44:2686-92.
9. Davatchi F, Sadeghi Abdollahi B, Tehrani Banihashemi A, Shahram F, Nadji A, Shams H, et al. Colchicine versus placebo in Behçet's disease: randomized, double-blind, controlled crossover trial. Mod Rheumatol 2009;19:542-9.
10. Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, et al. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis 2008;67:1656-62.
11. Hamuryudan V, Hatemi G, Tascilar K, Sut N, Ozyazgan Y, Seyahi E. et al. Prognosis of Behcet's syndrome among men with mucocutaneous involvement at disease onset: long-term outcome of patients enrolled in a controlled trial. Rheumatology 2010;49:173-7.
12. Hamuryudan V, Ozyazgan Y, Hizli N, Mat C, Yurdakul S, Tüzün Y, et al. Azathioprine in Behçet's syndrome. Effects on long-term prognosis. Arthritis Rheum 1997;40:769-74.
13. Sacli SF, Seyahi E, Ozyazgan Y, Mat C, Yazici H. Some manifestations disappear earlier than others in Behcet's syndrome (BS). Arthritis Rheum 2010;62 Suppl 10:S546.
14. Hamuryudan V, Hatemi G, Sut N, Ugurlu S, Yurdakul S, Yazici H. Frequent oral ulceration during early disease may predict a severe disease course in males with Behçet's syndrome. Clin Exp Rheumatol 2012;3 Suppl 72:s32-4.